Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ZJYL
stocks logo

ZJYL

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Valuation Metrics

The current forward P/E ratio for Jin Medical International Ltd (ZJYL.O) is 0.00, compared to its 5-year average forward P/E of 0.00. For a more detailed relative valuation and DCF analysis to assess Jin Medical International Ltd 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
0.00
Current PE
0.00
Overvalued PE
0.00
Undervalued PE
0.00

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Gross Profit Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

ZJYL News & Events

Events Timeline

(ET)
2025-07-16
05:41:21
Jin Medical launches production at Plant No. 3
select
2025-05-06 (ET)
2025-05-06
17:47:51
Jin Medical receives noncompliance notification from Nasdaq
select
2024-10-10 (ET)
2024-10-10
08:11:23
Jin Medical announces initiation of construction of new manufacturing facility
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.5
10-31Benzinga
Amazon Shares Surge Over 12%; Check Out 20 Stocks Making Moves in Premarket Trading

  • Amazon's Strong Performance: Amazon.com Inc reported third-quarter net sales of $180.2 billion, a 13% increase year-over-year, surpassing expectations, and its shares rose 12.5% in pre-market trading.

  • Fourth-Quarter Projections: The company anticipates fourth-quarter net sales between $206.0 billion and $213.0 billion, reflecting a year-over-year growth of 10% to 13%.

  • Pre-Market Stock Movements: Several stocks experienced significant pre-market trading movements, with DEFSEC Technologies Inc gaining 74.3% and Intensity Therapeutics Inc dropping 38.3%.

  • Mixed Results for Other Companies: Companies like SPS Commerce and Onespan reported disappointing financial results, leading to declines in their stock prices, while others like Alphatec Holdings Inc and Ardelyx Inc saw gains after better-than-expected quarterly results.

[object Object]
Preview
2.0
09-10NASDAQ.COM
Biotech Stocks Surge in After-Hours Trading Following Trial News, Insider Purchases, and Conference Excitement

  • Biotech Stock Movements: Several small- and mid-cap biotech stocks experienced significant gains in after-hours trading on September 9, 2025, driven by clinical updates, insider buying, and upcoming investor conferences, with notable performances from Immutep, Nautilus Biotechnology, and Pliant Therapeutics.

  • Immutep's Clinical Trial Update: Immutep's shares rose 4.37% after announcing that data from its Phase II trial for eftilagimod alpha will be presented at the CTOS 2025 conference, focusing on a rare cancer with high unmet need.

  • Nautilus Biotechnology Insider Buying: Nautilus Biotechnology's stock surged 12.25% following CEO Sujal M. Patel's significant insider purchases, indicating confidence in the company's future, alongside participation in an upcoming investor conference.

  • Kura Oncology's Regulatory Milestones: Kura Oncology's shares increased 6.12% after presenting at the H.C. Wainwright conference, highlighting key developments and upcoming regulatory milestones for its menin inhibitor targeting acute myeloid leukemia.

[object Object]
Preview
2.0
09-09NASDAQ.COM
Biotech Stocks Soar in After-Hours Trading: CAPR and TMDX Top the List Following Trial News and Earnings Boost

  • Biotech Stocks Surge: Several biotech and medical technology stocks experienced significant gains in after-hours trading, driven by earnings optimism, clinical trial progress, and speculative positioning, with notable movers including Seres Therapeutics and TransMedics.

  • Key Developments: TransMedics received FDA approval for its heart trial, while Capricor announced a milestone in its vaccine trial. Other companies like Karyopharm and Coya Therapeutics saw stock rebounds despite lacking specific news catalysts, indicating investor anticipation for future developments.

  • Market Volatility: Stocks such as Meihua International and Jin Medical showed notable price movements without specific news, reflecting technical rebounds and investor positioning in a volatile market environment.

  • Earnings Reports and Guidance: TransMedics raised its revenue guidance for 2025, projecting significant growth, while other companies are preparing for upcoming earnings reports and trial milestones, contributing to the overall market momentum in the biotech sector.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Jin Medical International Ltd (ZJYL) stock price today?

The current price of ZJYL is 0.2331 USD — it has decreased -1.27 % in the last trading day.

arrow icon

What is Jin Medical International Ltd (ZJYL)'s business?

Jin Medical International Ltd is a holding company mainly engaged in the design and manufacturing of wheelchairs. The Company, through its wholly owned subsidiaries, is primarily engaged in the design, development, manufacturing and sales of wheelchair and other living aids products to be used by people with disabilities or impaired mobility. The Company's wheelchair product category includes mid, high and low-end wheelchairs. The wheelchair components include wheels and brakes, which are sold to customers for after-sales service. The living aids product category consists of oxygen concentrators, bath aids and rehabilitative devices. The Company mainly distributes its products in domestic and overseas markets.

arrow icon

What is the price predicton of ZJYL Stock?

Wall Street analysts forecast ZJYL stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ZJYL is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Jin Medical International Ltd (ZJYL)'s revenue for the last quarter?

Jin Medical International Ltd revenue for the last quarter amounts to 34.23 USD, increased 5.98 % YoY.

arrow icon

What is Jin Medical International Ltd (ZJYL)'s earnings per share (EPS) for the last quarter?

Jin Medical International Ltd. EPS for the last quarter amounts to USD, decreased % YoY.

arrow icon

What changes have occurred in the market's expectations for Jin Medical International Ltd (ZJYL)'s fundamentals?

The market is revising No Change the revenue expectations for ZJYL for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -62.40%.
arrow icon

How many employees does Jin Medical International Ltd (ZJYL). have?

Jin Medical International Ltd (ZJYL) has 269 emplpoyees as of December 05 2025.

arrow icon

What is Jin Medical International Ltd (ZJYL) market cap?

Today ZJYL has the market capitalization of 36.49M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free